Health
China’s Sinovac reports mixed findings in early coronavirus vaccine trials – The Washington Post
Study found the vaccine candidate produced a quick immune response but lower levels of antibodies than in recovered coronavirus patients.
These early results put Sinovac on the back foot to prove its vaccine is effective in ongoing Phase 3 trials.
That is a concern, said Thomas Campbell, associate dean for clinical research at the University of Colorado, of the low antibody levels in Sinovacs Phase 2 trial. Its an important point here, in terms of comparing this vaccine to, for instance, the Moderna and Pfizer vaccines.
As the world awaits a coronavirus vaccine, some in China get early doses
Indonesia, the worlds fourth-most populous…
-
Noosa News12 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business16 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business12 hours ago1 ASX dividend stock down 43% I’d buy right now
-
General22 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts